InvisiShield Technologies Announces Scientific Advisory Board

EMERYVILLE, CA–(BUSINESS WIRE). consists of four experts in immunology and virology, including two Nobel Prize winners. The SAB will provide strategic and scientific advice to InvisiShield’s management and R&D team to advance preventive intranasal spray technologies against respiratory viruses.

“We are honored to welcome these leading experts in the fields of virology and immunology to our new Scientific Advisory Board,” said Dr. Warner Greene, President, Chief Scientific Officer and co-founder of InvisiShield. “The expertise these members bring to our team will be invaluable as we develop our intranasal preventatives.”

InvisiShield Scientific Advisory Board:

  • Melanie Ott, MD, Ph.D. (Chair) – dr Ott is Director of the Gladstone Institute of Virology (GIV), Senior Investigator at the Gladstone Institutes and Professor of Medicine at the University of California, San Francisco (UCSF). dr Ott’s research focuses on using viruses to find fundamental new biology in host cells. She made important discoveries about how viruses hijack human cells and contributed to efforts to eradicate HIV by gaining insight into viral transcription control. Since the outbreak of the COVID-19 pandemic, Dr. Ott focused her team on SARS-CoV-2, including the development of an amplification-free CRISPR-Cas13a assay for the direct detection of SARS-CoV-2.
  • Jennifer A. Doudna, Ph.D. – dr Doudna received the 2020 Nobel Prize in Chemistry for her co-discovery of the CRISPR-Cas9 gene editing system. She is Chancellor of Li Ka Shing and Professor in the Departments of Chemistry and Molecular and Cellular Biology at the University of California, Berkeley, Investigator at Howard Hughes Medical Institute, Faculty Scientist at Lawrence Berkeley National Laboratory, Department of Energy (Berkeley Laboratory). dr Doudna is also a researcher at the Howard Hughes Medical Institute, Principal Investigator at the Gladstone Institutes and President of the Innovative Genomics Institute. In response to the COVID-19 pandemic, Dr. Doudna developed tools for rapid COVID-19 testing and studied the transmissibility of SARS-CoV-2 variants.
  • Charles M. Reis, Ph.D. – dr Rice received the 2020 Nobel Prize in Physiology or Medicine for his co-discovery and characterization of the hepatitis C virus (HCV). dr Rice holds the Maurice R. and Corinne P. Greenberg Chair in Virology and is Chief of the Laboratory of Virology and Infectious Diseases at Rockefeller University. dr Rice has used CRISPR technology to identify new therapeutic targets for SARS-CoV-2 and translated techniques developed in his work on hepatitis C to screen drugs for their ability to inhibit coronavirus. dr Rice is a co-author of over 450 articles in the field of virology, serves as a referee for numerous peer-reviewed journals, and is past President of the American Society for Virology.
  • Akiko Iwasaki, Ph.D. – dr Iwasaki is Sterling Professor of Immunobiology and Molecular, Cellular, and Developmental Biology at Yale University and an Investigator at the Howard Hughes Medical Institute. She is Co-Lead Investigator of the Yale COVID-19 Recovery Study. She is also leading several other studies investigating the pathobiology of long-COVID, both in patients and through the development of animal models of long-COVID. She has received numerous awards, including the Eli Lilly and Company Research Award, the Burroughs Wellcome Fund Career Award in Biomedical Sciences, and the American Association of Immunologists (AAI) Thermo Fisher Meritorious Career Award.


The InvisiShield COVID-19 Intranasal Preventive (IS101) is designed as a topical nasal spray for daily use to provide immediate protection against SARS-CoV-2 infection, regardless of vaccination or a person’s immune system status. IS101 binds SARS-CoV-2 and features proprietary nasal retention technology. It has the ability to “capture and kill” all major current and potential future SARS-CoV-2 variants in the nasal cavity, the primary entry point of infection. In preclinical studies, IS101 provided at least 10 hours of protection against infection in mice.


InvisiShield Technologies Ltd. (formerly known as InvisiMask Technologies Ltd.) was founded by Dr. Warner Greene and Dr. Cheng Liu using technologies originally developed by Eureka Therapeutics, Inc. to protect COVID-19 from all major current and potential future SARS-CoV-2 variants using our proprietary “Capture and Kill” technology. Our proprietary technology platform is applied to other respiratory viruses including influenza and RSV.

InvisiShield Technologies Ltd. is headquartered in the San Francisco Bay Area. For more information on InvisiShield, visit

READ :  Too little sleep makes people less generous

Leave a Reply

Your email address will not be published. Required fields are marked *